ABT vs VXRT · P/E 25, rev $44.33B vs rev $28.7M
Abbott Laboratories (ABT) versus Vaxart Inc (VXRT) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
Vaxart Inc (VXRT) is a biotechnology company listed on US.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported VXRT revenue for 2024-12-31 was $28.7M. Net income was -$66.9M. Revenue was up 288.9% from 2023-12-31 to 2024-12-31. VXRT currently screens at market cap $73.0M.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. VXRT currently screens at market cap $73.0M.
Not investment advice. Open the ABT and VXRT stock pages for the full models.
Not investment advice.